As a first proof of concept towards an Aβ-lowering strategy involving NEP, a treatment with an agonist selective for SST1 and SST4 could ameliorates the Aβ pathology and improves cognitive outcomes in the App knock-in AD mouse model as schematized in Figure 8 (Nilsson et al., 2020). This evidence concerns the gene SSTR4 and Alzheimer disease.